Enfortumab Vedotin

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 696 publications

Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.

Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: April 14, 2026

New and Emerging Drug Reactions.

New and Emerging Drug Reactions.

Journal: Dermatologic clinics

Published: April 08, 2026

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.

Journal: Future oncology (London, England)

Published: April 02, 2026

Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.

Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.

Journal: The Journal of international medical research

Published: March 26, 2026

Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer.

Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: March 17, 2026

Recent highlights and breakthroughs in immunotherapy for head and neck cancers.

Recent highlights and breakthroughs in immunotherapy for head and neck cancers.

Journal: Current opinion in oncology

Published: March 06, 2026

Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.

Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: March 03, 2026

Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer.

Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer.

Journal: Nature reviews. Clinical oncology

Published: March 02, 2026

Re: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Re: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Journal: European urology

Published: February 27, 2026

Integrated inference of cancer gene expression from cell-free plasma chromatin.

Integrated inference of cancer gene expression from cell-free plasma chromatin.

Journal: bioRxiv : the preprint server for biology

Published: February 27, 2026

First-Line Enfortumab Vedotin Plus Pembrolizumab in Platinum-Ineligible Urothelial Carcinoma: A Three-Case Series.

First-Line Enfortumab Vedotin Plus Pembrolizumab in Platinum-Ineligible Urothelial Carcinoma: A Three-Case Series.

Journal: Cureus

Published: February 26, 2026

Unresolved questions in the sequencing of systemic therapy for advanced urothelial carcinoma.

Unresolved questions in the sequencing of systemic therapy for advanced urothelial carcinoma.

Journal: World journal of urology

Published: February 20, 2026

Showing 1-12 of 696

Last Updated: 04/28/2026